Detailed Narrative
Q4 FY26 Financial Performance Overview
Sigachi Industries reported a total operating income of INR 121.89 crores for Q4 FY26. The company achieved an EBITDA of INR 15.4 crores, resulting in an EBITDA margin of 12.63%. Net profit for the quarter stood at INR 7.6 crores, with a PAT margin of 6.23%. The MCC segment was the primary revenue driver, contributing INR 85.33 crores, while the API and O&M segments added INR 17.06 crores and INR 14.63 crores, respectively.
Ambitious FY27 Guidance and Growth Drivers
The company has set a robust revenue guidance for FY27, targeting INR 650-675 crores, alongside an EBITDA margin of 18-20%. This growth is anticipated to be fueled by incremental capacities from the Dahej and Jhagadia facilities, an improved product mix, and strong performance in the API and O&M segments. Specifically, API revenue is projected to grow significantly from INR 60 crores in FY26 to over INR 100 crores in FY27, contributing 18-20% to the total revenue.
Capacity Expansion and Commercialization Timelines
Sigachi is on track with its capacity expansion projects. The 12,000 metric tons per annum MCC capacity project at Dahej is expected to achieve Commercial Operation Date (COD) by the end of FY27, which will increase the total cellulose-based excipient capacity to 30,000 metric tons per annum. Additionally, the 1,800-ton CCS facility at Dahej SEZ, aimed at higher-value excipients, is slated for commercialization in Q1 FY28. The new MCC capacity is expected to generate INR 200-220 crores in revenue, with the CCS facility adding another INR 100 crores.
Operational Recovery and Margin Normalization
Following an incident, the company prioritized safety protocols, which temporarily impacted production and led to under-utilization. However, MCC capacity utilization, which was 75-80% in Q4 FY26, is expected to improve to 90-95% in FY27. Management anticipates a gradual recovery in EBITDA margins, targeting normalcy (15-20% range) by FY27 or mid-FY28, with CCS margins expected to be even higher than 20% due to its superior profitability profile.
Hyderabad Plant Status and Insurance Claim Update
The Hyderabad plant remains entangled in legal issues, prompting the company to strategically focus on new facilities at Dahej to avoid potential delays and resource allocation challenges. The insurance claim for the incident, initially expected by March 31, 2026, has experienced a slight delay. Management now anticipates receiving an ad hoc amount by the end of June 2026, with total claims for fixed asset and inventory loss amounting to INR 53.5 crores, and an additional INR 16.5 crores expected for business interruption loss.
Capital Expenditure and Funding Strategy
The capital expenditure for the 12,000 metric tons MCC expansion is estimated at INR 106 crores, and the CCS project at approximately INR 90 crores, with these investments phased across the current and next fiscal years. The funding strategy for these projects is currently under discussion, exploring options such as internal accruals, term loans, and potential equity fundraising. A definitive resolution regarding the funding mix is expected to be announced at an appropriate time⏳.
Strategic Initiatives and Future Outlook
Sigachi is actively progressing on CEP filing for its API R&D center, a move aimed at expanding into regulated markets. The Middle East Joint Venture has been temporarily put on hold for approximately six months due to the prevailing global geopolitical situation. The company's long-term vision includes a gradual increase in promoter shareholding and an aspirational target to achieve INR 1000 crores in total revenue by FY29.